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Brief Report
CD146+ bone marrow stromal cells have been recently rec-
ognized as clonogenic osteoprogenitors able to organize a
complete hematopoietic microenvironment. In this study
we used immunohistochemical analysis to investigate the
contribution of CD146+ bone marrow osteoprogenitors to
the stromal remodeling occurring in the different stages of
primary myelofibrosis. We found that CD146+ cells sited at
the abluminal side of the bone marrow vessels and branch-
ing among hematopoietic cells significantly increased in the
advanced stages of primary myelofibrosis (p<0.001), paral-
leling the extent of fibrosis (ρ=0.916, p<0.0001) and the
microvascular density (r=0.883, p<0.0001). Coherently
with a mural cell function, such cells also displayed
smooth-muscle actin expression. Our data providing evi-
dence of CD146+ cell involvement in bone marrow stromal
changes occurring in primary myelofibrosis are consistent
with the capability of these cells to participate in fiber dep-
osition, angiogenesis, and bone formation. They could also
represent a rationale for new therapies targeting the bone
marrow stroma in primary myelofibrosis.
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ABSTRACT
Introduction
Primary myelofibrosis is a Ph- hematopoietic stem cell
(HSC) disorder characterized by the clonal proliferation of the
myeloid and megakaryocytic populations and by the progres-
sive development of reticulin and collagen fibrosis in the bone
marrow (BM) parenchyma.1 Due to its fibrogenic nature, lead-
ing to BM failure, primary myelofibrosis (PMF) has a poor
prognosis and still lacks a valid therapeutic approach. 
Besides the proliferation of the hematopoietic cell lineag-
es, also the BM stromal reaction seems to paly a role in the
pathogenesis of this disease. This is suggested by the
increase in vessel neoformation and microvascular sprouting
which can be observed throughout the different phases of
the disease, and by the bone remodeling and formation
(osteosclerosis) occurring in the advanced stages.2 The active
role of the BM stroma is also supported by the increase in
the microvessel density that can be observed in PMF paral-
leling the degree of BM fibrosis and retaining, along with
fibrosis, a prognostic significance.3-5
Recently, the growing attention on the BM stromal niches
and their cellular constituents has led to the identification of
CD146 (MCAM)-expressing BM stromal cells as clonogenic
BM osteoprogenitors, deriving from hematopoietic stem cells,
able to induce bone formation and to organize a hematopoiet-
ic microenvironment.6,7 In the human BM in situ, such a BM
stromal stem-cell (BM-SSC) phenotype has been shown to be
shared by subendothelial (adventitial) reticular cells displaying
mural-cell properties (e.g. smooth muscle actin expression,
reticulin and collagen fiber deposition).6-8 Furthermore,
CD146+ BM subendothelial cells have been shown to be able
to sustain microvessel assembly and remodeling through the
production of Angiopoietin-1 and its interaction with Tie-2
receptor on endothelial cells.6 On the basis of these observa-
tions, we hypothesized that such cells could play a role in the
BM stromal changes occurring in PMF and wanted to assess
the presence and distribution of CD146+ osteoprogenitors in
the bone marrow of patients with different stages of PMF,
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namely early- (grade 0/1 fibrosis) and advanced-stages
(grade 2/3 fibrosis), by the means of immunohistochem-
ical analysis.
Design and Methods
This study was performed with the approval and per-
mission of the Institutional Review Board of the
University Hospital “Policlinico Paolo Giaccone” of
Palermo. All the procedures followed were in accordance
with the Helsinki Declaration.
Sample selection
The study was performed on bone marrow trephine
biopsies obtained from 32 patients who were diag-
nosed with PMF according to the WHO criteria9
between January 2005 and December 2007 at the
Department of Human Pathology of the University of
Palermo. Only representative bone marrow trephine
biopsies (i.e. non-tangential biopsies of more than 1.5
cm in length) collected at the time of diagnosis, before
any treatment was started, were included in the study.
Ten bone marrow biopsies from age-matched patients
with Hodgkin’s lymphoma without BM involvement
were used as controls. BM biopsies were fixed in for-
malin and paraffin embedded and 4 mm-thick sections
were cut from paraffin blocks for histochemical and
immunophenotypical evaluation. The following clini-
cal data were retrospectively gathered from the
patients’ medical records: age, gender, white blood cell
count, platelet count, hemoglobin value, presence of
one or more risk factors included in the Mayo prog-
nostic score10 (Hb<10 g/dL, WBC<4 or >30×109/L,
PLT<100×109/L, AMC >1×109/L), and JAK2 (V617F)
mutational status.
Bone marrow histochemical and immunophenotypical
analysis
On histopathological evaluation, all the previous diag-
noses of PMF were confirmed. Assessment of the BM
fibrosis was performed on Gomori’s silver stained sec-
tions on the basis of the European Myelofibrosis
Network (EUMNET) consensus grading and scored
accordingly from grade 0 to 3.11 All the cases were inde-
pendently assessed by four of the authors (UG, EB, CT,
AMF) and interobserver agreement on BM fibrosis was
reached by re-examining discordant cases on a multi-
headed microscope. Immunohistochemistry was per-
formed on BM sections by means of the streptavidin-
biotin-peroxidase complex with rhodamine-red amino-
ethyl carbazole as chromogen. The following primary
antibodies were used: mouse monoclonal anti-CD34
(clone QBEnd/10, Novocastra, UK), mouse monoclonal
anti-CD146 (clone N1238, Novocastra, UK), mouse mon-
oclonal anti-SMA (clone 1A4, Dako, Denmark). The
microvascular density was assessed by counting the
absolute number of CD34+ vessels out of 10 high-power
(400×) microscopical fields (HPF) and was expressed as
the mean value. CD146 was similarly evaluated by
counting the number of positive cells out of 10 HPF and
was expressed as the mean value. 
Statistical analysis
The Mann Whitney U-test was performed to compare
two independent groups of data. Bivariate correlation
was tested by the means of Spearman’s rho test. Results
of the statistical analysis were considered significant for
p values <0.05. All calculations and plots were performed
using the SPSS 13.0 statistical software package. 
Results and Discussion
Clinical, histological, and immunophenotypical features
of early- and advanced-PMF cases are summarized in Table
1. The assessment of CD34 immunostaining revealed a
noticeable increase in the MVD in PMF cases as compared
to control cases (p=0.003) and, consistently with previous
observations, in PMF cases the MVD paralleled the
increase in fiber content (Spearman’s ρ=0.880, p<0.001)
(Figure 1A).3,4 CD146 proved to be expressed by reticular
cells sited at the abluminal side of the BM vasculature
extending dendritic processes among hematopoietic cells
(Figure 2A). These cells with adventitial position and retic-
ular morphology also expressed SMA, which confirmed
their mural cell phenotype (Figure 2B). In control samples
very few CD146+ cells were detected. No labeling for
CD146 was detected in hematopoietic cells or in other BM
stromal cell types (adipocytes, macrophages, osteoblasts
and osteocytes, endosteal cells) in controls and PMF cases.
In the early stages of PMF (grade 0/1 cases), CD146 expres-
sion was similar to that observed in control samples. A
marked increase in CD146 expression was found in the
advanced phases of PMF, with CD146+ subendothelial
meshwork being more extended and denser than that of
early phases (p<0.001) (Figure 1B, Figure 2C-H).
Furthermore, CD146 proved to be significantly associated
Table 1. Clinical and pathological characteristics of the 32 primary myelofi-
brosis patients.
Characteristic Early PMF Advanced PMF p*
Number of patients 16 16 −
Median age, years (range) 68 (42-84) 71 (48-85) n.s.
M/F (ratio) 8/8 (1) 10/6 (1.6) n.s.
Degree of fibrosis (EUMNET score):
n. of pts. (%) PMF-0: 7 (43) PMF-2: 9 (57) −
PMF-1: 9 (57) PMF-3: 7 (43)
Hb, g/L, median (range) 133 (94-162) 102 (71-123) 0.001
Hb<10 g/L, n. of pts (%) 2 (12) 7 (43) n.s.
WBC, ×109/L, median (range) 9.6 (6.3-13.9) 11.3 (5.2-37) n.s.
WBC<4 or >30×109/L, n. of pts (%) 0 (0) 2 (12) n.s.
Plt, ×109/L, median (range) 793 (422-1071) 403 (32-731) 0.023
Plt <100×109/L, n. of pts (%) 0 (0) 2 (12) n.s.
AMC >1×109/L, n. of pts (%) 1 (6) 3 (19) n.s.
JAK2V617F status
n. of pts (%) M: 8 (50) M: 9 (56) n.s.
U: 7 (44) U: 7 (44)
NA: 1 (6) NA: 0 (0)
CD146+ cell count, median (range) 2 (1-5) 7 (3-15) <0.0001
MVD, median (range) 7 (5-9) 14 (8-22) <0.0001
PMF: primary myelofibrosis; M/F: male-to-female ratio; Hb: hemoglobin;WBC: white blood
cells; Plt: platelets; AMC,absolute monocyte count; MVD: microvascular density. *Statistical
significance based on the Mann-Whitney U test, p values < 0.05 were considered significant.
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CD146+ stromal cells in primary myelofibrosis
Figure 1. (A) Comparison between microvascular density in controls, early and advanced stage of primary myelofibrosis. Microvascular den-
sity shows a remarkable increase in primary myelofibrosis cases. (B) Comparison between CD146 expression in controls, early and
advanced primary myelofibrosis cases. Advanced primary myelofibrosis cases display a noticeable increase in CD146 positive cells com-
pared to early stage and controls, while the differences between early stage cases and controls are less remarkable. (C) The graph shows
the significant association between the number of CD146 positive cells and the degree of fibrosis, graded according to the EUMNET con-
sensus criteria. Larger dots represent a higher number of cases. (D) The graph shows a significant association between number of CD146
positive cells and the microvascular density in different phases of primary myelofibrosis. Larger dots represent a higher number of cases. 
Figure 2. C-H. Differences in microvascular density and in the number of CD146 posi-
tive cells betwen an early (C, D, E; grade-1 fibrosis) and an advanced primary myelofi-
brosis (F, G, H; grade-2 fibrosis). CD146 positive subendothelial cells form a wider and
denser meshwork in the advanced stage (G) of primary myelofibrosis than in the early
subendothelial stage (D). The slight increase in microvascular density observed in the
early stage (C) is not associated with a remarkable increase in CD146 expression (D)
(C, F: CD34 immunostaining; D, G: CD146 immunostaining; E, H: Gomori’s staining;
original magnification 200×). 
Figure 2. A-B. Sections from a case of
advanced (grade-2) primary myelofibrosis
showing that subendothelial cells, branching
into the surrounding hematopoietic parenchy-
ma (violet arrows), stain positive either for
CD146 (A) or smooth muscle actin (B), while
endothelial cells are negative (black arrows)
for both antibodies. Inset: the distinction
between CD34 positive endothelial cells
(blue) and CD146 positive adventitial cells
(red) is highlighted by double immunostain-
ing. (Strept-ABC, original magnification 400x). 
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with the degree of fibrosis (Spearman’s rho=0.916,
p<0.0001) (Figure 1C) as well as with the MVD
(Spearman’s ρ=0.883, p<0.0001) (Figure 1D). However, the
slight increase in the microvascular density which was
observed in the early phases of the disease (grade 0/1) was
not paralleled by a corresponding increase in CD146+ cells
(Figure 2C-D). This finding further supports the evidence
that the increase in microvascular density occurs as an
early, though variably intense, phenomenon in the PMF
pathogenesis,12 and suggests a prevalent contribution of
CD146+ cells to the advanced stages of the disease. 
The strong association we found between the CD146 cell
count and the degree of fibrosis prompted us to test for pos-
sible associations occurring between these two variables
and the clinical data of the 32 PMF patients (listed in Table
1). Both the CD146 cell count and the degree of fibrosis
proved to be significantly associated with a lower Hb value
(ρ=-0.745, p=0.001 and ρ=-0.798 p<0.0001, respectively)
and PLT count (ρ=-0.630, p=0.009 and ρ=-0.657, p=0.006
respectively) on diagnosis. These data are in keeping with
those from previous observations indicating that the pro-
gression of the BM stromal reaction is often matched by
the decline of hematopoietic function.5,13
Interestingly, the CD146 cell count also correlated with
the presence of risk factors on diagnosis (ρ=0.634,
p=0.008), while the association of this latter with the
extent of fibrosis did not reach statistical significance. No
associations were found with the remaining presenting
features, including the JAK2 mutational status. However,
the analysis of the JAK2V617F allele burden, which was
not performed in this study, could possibly lead to differ-
ent results. Moreover, due to the descriptive design of this
study and the small number of cases included, the results
coming from such a clinicopathological analysis should be
considered with caution.
Overall, our results suggest the involvement of CD146+
subendothelial reticular cells the stromal remodeling that
occurs in the advanced stages of PMF. In this setting,
CD146+ cells might play a role mainly through their recent-
ly reported function of clonogenic osteoprogenitor cells
responsible for new bone formation6 and through the
direct production and deposition of reticulin and collagen
fibers. CD146+ cells might also support BM neoangiogene-
sis through the angiopoietin-1/Tie-2 pathway, comple-
mentary to that of VEGF which has been recently
described in Ph- CMPDs.14
In conclusion, our data on the participation of CD146+
subendothelial osteoprogenitors in PMF stromal changes
could represent a rationale for new studies focusing on
these cells as targets for new therapies affecting the BM
stroma. To this purpose, along with CD146, other recently
identified BM-SSC markers like CD200, and CD73 could
possibly be taken into consideration.15
Further studies are also needed to investigate the clonal
nature of CD146+ BM cells in PMF and their possible prog-
nostic relevance.
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